Allogene Therapeutics News

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Conference Call and Webcast Scheduled for May 13, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage

GlobeNewswireMay 6 20:30

12 Health Care Stocks Moving In Monday's Pre-Market Session

GainersMonogram Orthopaedics (NASDAQ:MGRM) stock increased by 19.1% to $2.31 during Monday's pre-market session. The company's market cap stands at $73.1 million. Allarity Therapeutics (NASDAQ:ALLR) s

BenzingaMay 6 20:06

Earnings Week Ahead: Disney, Palantir, Shopify, Uber, Plug Power and More

Seeking AlphaMay 5 20:00

Allogene Therapeutics Awarded $15M Grant From California Institute For Regenerative Medicine To Advance Development Of Allogeneic CAR T In Renal Cell Carcinoma

$15 million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)ALLO-316 Illustrates Proof-of-Concept in RCC an

BenzingaApr 26 20:35

Allogene Therapeutics Announces Q2 Investor Conference Participation

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T)

GlobeNewswireApr 9 20:30

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Yahoo FinanceApr 7 22:22

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)

TipRanksMar 19 20:11

HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Allogene Therapeutics with a Buy and maintains $10 price target.

Analyst UpgradesMar 19 18:55

Allogene Therapeutics Poised for Growth: A Strong Buy Rating Amidst Innovative Trials and Strategic Advancements

TipRanksMar 19 13:46

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript

Yahoo FinanceMar 17 04:35

Allogene Therapeutics' Stability Threatened by Banking Sector Turmoil

TipRanksMar 16 14:01

RBC Capital Reiterates Outperform on Allogene Therapeutics, Maintains $10 Price Target

RBC Capital analyst Luca Issi reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Outperform and maintains $10 price target.

BenzingaMar 16 00:19

Allogene Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/15/2024 115.29% RBC Capital → $10 Reiterates Outperform → Outperform 02/27/2024 72.23% JP Morgan $9 → $

BenzingaMar 16 00:17

Allogene Therapeutics: Redefining LBCL Treatment With Innovative ALPHA3 Trial and Promising Cema-cel Therapy

TipRanksMar 15 21:35

Allogene Therapeutics: Advancing Clinical Studies and Promising Treatment Differentiation Set Stage for Stock Value Growth

TipRanksMar 15 19:15

Allogene Therapeutics (ALLO) Gets a Buy From RBC Capital

TipRanksMar 15 18:47

Allogene Therapeutics Files $500 Million Mixed Shelf

Allogene Therapeutics (ALLO) filed a registration statement Thursday for the potential sale of up to $500 million of securities from time to time. The filing covers the sale of the company's common st

MT NewswiresMar 15 15:27

Analysts Conflicted on These Healthcare Names: Allogene Therapeutics (ALLO), Aquestive Therapeutics (AQST) and Allakos (ALLK)

TipRanksMar 15 12:40

Earnings Call Summary | Allogene Therapeutics(ALLO.US) Q4 2023 Earnings Conference

The following is a summary of the Allogene Therapeutics, Inc. (ALLO) Q4 2023 Earnings Call Transcript:Financial Performance:Allogene Therapeutics ended Q4 2023 with a solid cash balance of $448.7 mill

Futu NewsMar 15 09:04 · Conference Call

Allogene Therapeutics Files for $500M Mixed Shelf

Seeking AlphaMar 15 05:37